Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Vir Biotechnology Announces Chief Financial Officer Transition
09:00am, Friday, 24'th Jul 2026
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Princi
Vir Biotechnology Announces Chief Financial Officer Transition
08:30am, Friday, 24'th Jul 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Fina
Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results
04:05pm, Wednesday, 22'nd Jul 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate u
Vir Biotechnology: Multiple Catalysts In Hepatitis And Oncology Ahead
08:45am, Thursday, 16'th Jul 2026
Vir Biotechnology is entering a catalyst-rich period with key clinical trial readouts from the ECLIPSE program in hepatitis delta plus updates from its T-cell engagers in oncology indications. VIR has
Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors
04:05pm, Wednesday, 10'th Jun 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsir
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
10:59am, Monday, 18'th May 2026
Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified research pipeline.
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
03:47pm, Sunday, 17'th May 2026
Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.
Vir Biotechnology: Trading Near Cash Value With A Huge Revenue Opportunity
03:38am, Saturday, 16'th May 2026
Vir Biotechnology is rated a buy, supported by a strong cash position, pivotal late-stage pipeline, and deep institutional backing. VIR's lead CHD drugs, Tobevibart and Elebsiran, target a large, unde
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:30pm, Tuesday, 12'th May 2026
Vir Biotechnology, Inc. (VIR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
06:02am, Thursday, 07'th May 2026
Vir Biotechnology, Inc. (VIR) Q1 2026 Earnings Call Transcript
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
04:05pm, Wednesday, 06'th May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. “Vir Bio delivered
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
04:05pm, Tuesday, 05'th May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the B
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
04:05pm, Thursday, 23'rd Apr 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate upd
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
08:05am, Thursday, 16'th Apr 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed foll
